 |
|
Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan
Yosuke Shimodaira, Kengo Onochi, Kenta Watanabe, So Takahashi, Sho Fukuda, Noboru Watanabe, Shigeto Koizumi, Tamotsu Matsuhashi, Katsunori Iijima
Intest Res. 2021;19(2):225-231. Published online 2020 Aug 18 DOI: https://doi.org/10.5217/ir.2020.00023
|
|
Citations to this article as recorded by
 Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
Yuichiro Ohtaki, Kan Uchiyama, Hirotaka Kamiya, Eri Moriizumi, Moe Yamada, Yuma Aoki, Toshimune Watanabe, Sachie Kiryu, Shizuka Suzuki, Yoshihiro Matsumoto, Zensho Ito, Toshifumi Ohkusa, Shigeo Koido, Masayuki Saruta
BMC Gastroenterology.2022;[Epub] CrossRef
|